

Effects of Lorazepam on Saccadic Eye Movements: The Role of Sex, Task Characteristics and Baseline Traits

Ulrich Ettinger (1), Inga Meyhöfer (1), Mitul A. Mehta (2), Veena Kumari (3), Philip J. Corr (4), Steven C.R. Williams (2), Adam M. Perkins (5)

(1) Department of Psychology, University of Bonn, Bonn, Germany

(2) Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

(3) Centre for Cognitive Neuroscience, College of Health and Life Sciences, Brunel University London, Uxbridge, UK

(4) Department of Psychology, City, University of London, UK

(5) Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

Corresponding author:

Ulrich Ettinger
Department of Psychology
University of Bonn
Kaiser-Karl-Ring 9
D-53111 Bonn
Germany

Phone: +49 228 734208

Email: ulrich.ettinger@uni-bonn.de

Short Title:

Lorazepam Effects on Saccades

Abstract

Background: Saccadic eye movements are controlled by a network of parietal, frontal, striatal, cerebellar and brainstem regions. The saccadic peak velocity is an established biomarker of benzodiazepine effects, with benzodiazepines reliably reducing the peak velocity. **Aims:** In this study, we aimed to replicate the effects of benzodiazepines on peak velocity and we investigated effects on previously less studied measures of saccades. We also explored the roles of sex, task characteristics and the baseline variables age, intelligence and trait anxiety in these effects. **Method:** Healthy adults (N=34) performed a horizontal step prosaccade task under 1mg lorazepam, 2mg lorazepam and placebo in a double-blind, within-subjects design. **Results:** We replicated the dose-dependent reduction in peak velocity with lorazepam and showed that this effect is stronger for saccades to targets at smaller eccentricities. We also demonstrated that this effect is independent of sex and other baseline variables. Lorazepam effects were widespread, however, occurring on mean and variability measures of most saccadic variables. Additionally, there were sex-dependent lorazepam effects on spatial consistency of saccades, indicating more adverse effects in females. **Conclusions:** We conclude that saccadic peak velocity is a sensitive and robust biomarker of benzodiazepine effects. However, lorazepam has pronounced effects also on other parameters of horizontal saccades. Sex-dependent drug effects on spatial consistency may reflect cerebellar mechanisms, given the role of the cerebellum in saccadic spatial accuracy.

Keywords

Lorazepam, benzodiazepine, saccadic eye movements, oculography, biomarker, sex differences, anxiety

Introduction

The peak velocity of saccadic eye movements is an established biomarker of GABAergic benzodiazepine effects (Atack, 2008; Chen et al., 2012; De Visser et al., 2003). However, despite the widespread use of this measure in drug studies, there are a number of gaps in our knowledge of benzodiazepine effects on saccadic peak velocity. These concern primarily the role of baseline trait variables that may explain variance in benzodiazepine effects, such as sex, age, intelligence or anxiety; the effects of benzodiazepines on intra-individual variability of peak velocity; and the role of experimental task factors in these effects. Additionally, whilst saccadic peak velocity is frequently studied, there are other saccadic measures whose modulation by benzodiazepines has not yet been investigated. To address these questions, we carried out a comprehensive examination of the effects of lorazepam on peak velocity and other saccadic variables. Our aims were as follows.

First, we aimed to replicate the previously reported reduction of peak velocity by benzodiazepines (De Visser et al., 2003) using a horizontal, centrifugal, step saccade paradigm (Study Aim 1). We chose lorazepam as it is a widely prescribed drug for anxiety and a frequently used comparator compound in the examination of novel compounds (e.g., Atack, 2008; de Haas et al., 2009). We applied multiple doses of lorazepam (1mg, 2mg) in order to assess the dose-dependency of any effects.

Second, we aimed to characterise lorazepam effects on other saccadic variables, in addition to peak velocity (Study Aim 2). Whilst peak velocity is a well-established biomarker of benzodiazepine effects (De Visser et al., 2003), saccadic tasks yield a rich array of performance measures (Holmqvist et al., 2011; Leigh and Zee, 2015). The widespread expression of GABA_A receptors in brain (Uusi-Oukari and Korpi, 2010), especially the α 1 subunit thought to be responsible for the sedative effects of benzodiazepines (Chen et al., 2012), suggests that lorazepam influences likely manifest themselves throughout the neural network underlying saccades (Leigh and Zee, 2015), thereby affecting diverse performance measures.

For example, detailed analysis of the temporal waveform of saccades yields measures of average velocity, Q and skewness. Average velocity is calculated as the ratio of amplitude and duration and has been found to be reduced by lorazepam (Harron et al., 1995). Q refers to the ratio of peak and average velocity (Leigh and Zee, 2015). Benzodiazepine effects on Q have, to our knowledge, not

been investigated. This is important, as a reduction in Q would be indicative of a more pronounced effect on peak than average velocity, buttressing the primacy of peak velocity as a benzodiazepine biomarker. Skewness refers to the ratio between time to reach peak velocity (acceleration phase) and the total saccade duration (combining acceleration and deceleration phases) (Collewyn et al., 1988). Benzodiazepine effects on skewness have, to our knowledge, not been reported. Whilst two previous studies observed a reduction in acceleration/deceleration ratio with midazolam (Ball et al., 1991) and lorazepam (King et al., 1995), another study observed increased acceleration phase with diazepam (Roy-Byrne, Cowley, Radant, Hommer, & Greenblatt, 1993). However, these measures differ from skewness, as they do not take into account saccade duration (Leigh and Zee, 2015).

Another measure that has not been investigated in relation to benzodiazepine effects is saccadic curvature. The trajectories of horizontal saccades are rarely entirely straight but typically show some degree of curvature (Smit and Van Gisbergen, 1990; Yarbus, 1967). Curvature is influenced by attentional factors (Sheliga et al., 1994) and is related to neuronal activity in frontal eye fields and superior colliculus (Port and Wurtz, 2003), suggesting that exogenous GABAergic modulation of these neurons may affect this metric. However, to our knowledge, no previous study has investigated benzodiazepine influences on saccadic curvature in humans.

We also investigated saccade latency and measures of spatial accuracy. Latency reflects the speed of visual information processing, decision making and response execution processed in subcortical and cortical areas (Carpenter, 2004). Spatial accuracy is a function of sensorimotor transformations which involve dorsal stream cortical areas, but is also sensitive to cerebellar integrity (Robinson & Fuchs, 2001). Previous studies have found lorazepam to increase latency (Chen et al., 2014, 2015; de Haas et al., 2009; de Haas et al., 2007, 2008; Green, King, & Trimble, 2000; Masson et al., 2000; Tedeschi, Smith, Dhillon, & Richens, 1983) and reduce spatial accuracy (Chen et al., 2014, 2015; de Haas et al., 2009; de Haas et al., 2007, 2008; King et al., 1995; Masson et al., 2000).

Third, we wished to assess lorazepam effects not merely on mean performance measures, but also on measures of the intra-individual variability of performance (Study Aim 3). Intra-individual variability is an important phenomenon in studies of drug effects (Coghill et al., 2014) and psychopathology (Kuntsi and Klein, 2011). While one previous study showed that 1mg lorazepam increases the variance in saccadic latency (Masson et al., 2000), it is unknown whether lorazepam systematically affects intra-individual variability across saccadic measures.

Fourth, we aimed to investigate the role of sex¹ in the effects of lorazepam on saccadic variables (Study Aim 4). Sex is a primary domain of variation in biomedical research (Brooks and Clayton, 2017; Tannenbaum et al., 2016). However, much preclinical and clinical research includes only male humans or animals or fails to identify the subjects' sex (Brooks and Clayton, 2017). Studying sex differences is particularly relevant in the investigation of treatments for disorders that differ in their prevalence between males and females. Specifically, whilst females have an approximately two-fold higher risk for anxiety disorders than males (Kessler et al., 2011; Tolin and Foa, 2006), not enough is known about the role of sex in the pharmacological treatment of these disorders (Bekker and van Mens-Verhulst, 2007). Similarly, most previous studies of benzodiazepine effects on saccades were performed in males, and no study, to our knowledge, has considered the role of sex in the reported effects.

Fifth, we investigated the role of experimental task factors such as stimulus direction (right, left) and distance (near, far) in lorazepam effects (Study Aim 5). Such task factors, especially stimulus distance from centre, are known to affect saccadic performance (Leigh and Zee, 2015) but have not, to our knowledge, been investigated in relation to benzodiazepine effects.

Sixth, we explored the role of other relevant baseline trait variables along which individuals differ and which may relate to lorazepam effects, such as age, intelligence and trait anxiety (Study Aim 6). Inter-individual variation contributes significantly towards the heterogeneity of brain structure and function (Brooks and Clayton, 2017) and the ability to predict treatment response using such baseline measures remains a formidable challenge (Owen et al., 2013). The roles of age, intelligence and trait anxiety have, to our knowledge, not been considered in benzodiazepine effects on saccades.

Finally, we investigated whether the internal consistency of performance is affected by lorazepam (Study Aim 7). Reduced internal consistency of a measure, e.g. Cronbach's alpha, would be indicative of less consistent responding, possibly due to increased intra-individual variability.

¹ In this study, we use the term "sex" to denote biological sex, as indicated by participants' self-report. We acknowledge that in humans the term biological "sex" is confounded with, and difficult to separate from, the more psychosocial concept "gender" (Brooks and Clayton, 2017).

On the basis of the previous literature, our hypotheses were that lorazepam would have adverse effects on peak and average velocity, latency and duration. Further, we aimed to characterise lorazepam effects on mean and variability measures not previously considered and explore the roles of sex, age, intelligence, trait anxiety and task-related factors in lorazepam effects.

Method

Participants

Forty healthy volunteers were recruited via circular emails to staff and students of King's College London, UK. Participants underwent a thorough physical and psychiatric assessment by the study doctor before admission to the study to ensure they were in good physical and mental health. All participants had normal or corrected-to-normal vision.

The study was approved by King's College Hospital Research Ethics Committee. Participants gave written informed consent before participating.

Design and Procedure

The study employed a double-blind, placebo-controlled, within-subjects design with order of drug administration randomised. Each participant was assessed three times, under placebo (50mg ascorbic acid), 1mg lorazepam and 2mg lorazepam. Sessions were separated by at least a week to allow for adequate drug washout. Assessments took place in the afternoon, between 1.30pm and 6.30pm, with the time of assessment kept the same for each participant as closely as possible.

On study days, participants' current health was first verified by study staff. A capsule containing the drug or placebo was then administered p.o. with 300ml of water. After a 120 minutes wait for the drug to reach peak concentrations in blood (Kyriakopoulos et al., 1978), participants completed cognitive tasks lasting approximately 40 minutes, followed by the saccade task. The cognitive tasks have been described in detail elsewhere (Perkins et al., 2013a, 2013b).

Saccade Task

The saccade task was written using ExperimentBuilder (SR Research Ltd., Ontario, Canada). Participants were seated with their eyes 57cm from a 19-in monitor (visible screen area 360mm x 270mm, 1024 x 768 pixels, 60 Hz refresh rate), with the head on a chinrest. They were shown a stimulus on the monitor and were asked to follow it with their eyes as fast and accurately as possible without moving the head. The stimulus was a black circle (0.3°), presented on white background. Before each trial, a drift correction procedure was carried out. A trial began with the stimulus shown in the central position of the monitor for a random duration of 500-1500ms, before it stepped to one of four horizontal positions (right far (RF): +14.5°, right near (RN): +7.25°, left near (LN): -7.25°, left far (LF): -14.5°), where it remained for 1000ms. Each peripheral location was used 15 times in a random order, resulting in a total of 60 trials. Four practice trials were carried out before the task.

Movements of the right eye were recorded using a video-based corneal reflection and pupil tracker (Eyelink 1000, SR Research Ltd.) at 1000 Hz sampling rate. A 9-point calibration was carried out before the beginning of the task.

Saccade data were processed blind to drug group using EyeLink DataViewer (SR Research Ltd.) and Matlab (The Mathworks, Natick, MA, USA). For each trial, the first saccade following onset of the peripheral stimulus was included in analysis if (i) it was made in the direction of the peripheral stimulus, (ii) it had a minimum amplitude of 1°, (iii) it had a minimum latency to stimulus of 70ms, (iv) there was no blink or saccade in the window from 100ms before to onset of peripheral stimulus, (v) there was no blink within the saccade, and (vi) the saccade start position did not deviate from the central stimulus position by more than 50 pixels horizontally or vertically.

The following dependent variables were extracted for included saccades at each peripheral stimulus position ($\pm 7.25^\circ$, $\pm 14.5^\circ$).

- Latency: the time from peripheral stimulus onset to saccade onset (ms).
- Amplitude gain: the ratio of saccade amplitude divided by desired amplitude. A saccade with perfect spatial accuracy thus has a score of 1. Smaller scores indicate hypometric (undershooting) saccades and larger scores indicate hypermetric (overshooting) saccades.
- Spatial error: the residual position error. This measure was obtained by subtracting the desired saccade amplitude ($\pm 7.25^\circ$ or $\pm 14.5^\circ$, depending on peripheral stimulus location) from the actual saccade amplitude and dividing the result by the desired saccade amplitude.

The absolute value of this term reflects the residual error; this was then averaged across all saccades. A saccade with perfect spatial accuracy thus has a score of 0, and higher scores indicate greater spatial error, irrespective of saccadic overshoot or undershoot.

- Peak velocity: the maximal velocity of the saccade (°/sec).
- Average velocity: the mean velocity of the saccade (°/sec).
- Duration: the time from saccade onset to offset (ms).
- Curvature: the maximal deviation of vertical eye position during a saccade adjusted for the final vertical eye position in the saccade. This measure is calculated by subtracting the final eye position in the saccade from the maximal deviation of eye position during the saccade.
- Skewness: the ratio of acceleration and deceleration phases. This measure is calculated as the time (ms) from saccade onset to peak velocity divided by the time (ms) from peak velocity to saccade offset. A perfectly symmetrical saccadic waveform thus has a score of .5. Smaller scores indicate a shorter acceleration than deceleration phase, and larger scores indicate a shorter deceleration than acceleration phase.
- Q: the relationship between peak velocity and average velocity. This measure is calculated by dividing the peak velocity by the average velocity.

For each variable, each participant's mean score was calculated. Additionally, for latency, amplitude gain, peak and average velocity, duration as well as curvature, the intra-individual coefficient of variation (ICV) was calculated as a measure of variability by dividing a participant's intra-individual standard deviation by his/her mean score. Only participants who had at least 5 correct trials at each peripheral stimulus position were included in statistical analysis.

Psychometric Assessment

Age and sex were measured using a self-report questionnaire.

Intelligence was estimated using the 16PF reasoning ability scale (Cattell et al., 1970). This 13-item test is a validated short scale measure of intelligence (Abel and Brown, 1998). The possible score range is 0-13, with higher scores indicating better performance.

Trait anxiety was measured using the State Trait Anxiety Inventory (STAI) (Spielberger et al., 1983). This 20-item questionnaire is a well-established measure of trait anxiety. Higher scores indicate higher levels of anxiety.

Statistical Analysis

Statistical analysis was carried out using SPSS 22.0 (IBM, Armonk, NY, USA) unless otherwise noted.

To assess effects of lorazepam, mixed-model analyse of variance (ANOVA) were carried out for each dependent variable with the within-subjects factors Drug (placebo, 1mg lorazepam, 2mg lorazepam), Direction (right, left) and Distance (near, far) and the between-subjects factor Sex (male, female). Significant interactions were followed up with t-tests using Bonferroni correction of the alpha level.

To assess the role of demographic variables in lorazepam effects, change scores (placebo – drug) were calculated for each variable, separately for 1mg and 2mg doses. These change scores were correlated with age, STAI trait anxiety and 16PF reasoning score, using Bonferroni correction of the alpha level ($0.05 / 128 = 0.0004$).

To assess internal consistency, Cronbach's alpha was calculated over the individual trials for each variable in each Drug condition (1mg, 2mg, placebo), independent of Direction and Distance. To assess effects of lorazepam on internal consistency, Cronbach's alphas were compared across Drug conditions using the Cran R package cocron (Diedenhofen and Musch, 2016).

Results

Descriptive Statistics

A total of N=40 participants completed the study. Six participants were excluded from analyses as they did not meet the minimum number criterion of 5 trials per peripheral stimulus position, leaving a final sample of N=34 (Table 1).

Spatial error, Q, curvature and the ICVs of gain, peak velocity, duration, latency and curvature were positively skewed and, therefore, log-transformed. Descriptive statistics of all variables are in Table 2 (males) and Table 3 (females). ANOVA results are in Table 4.

=== INSERT TABLES ABOUT HERE ===

Drug and Task Effects on Performance

Study Aims 1-3.

Replicating previous studies, there was a significant main effect of Drug on saccadic peak velocity (Study Aim 1).

In addition, there were significant main effects of Drug on all other variables, both mean (Study Aim 2) and variability (Study Aim 3) measures, except duration ($p=0.87$), curvature ($p=0.82$) and ICV of spatial error ($p=0.55$). These results indicate negative effects of lorazepam: increased latency, reduced amplitude gain, increased spatial error, reduced peak velocity, reduced average velocity, increased skewness, reduced Q and increased ICV of latency, amplitude gain, peak velocity, average velocity, duration and curvature.

For explanatory purposes, note that increased skewness scores due to lorazepam reflect a relative increase in acceleration time and a relative decrease in deceleration time. Reduced Q due to lorazepam indicates a reduction in the ratio between peak and average velocity, suggesting that the reduction in peak velocity due to lorazepam was more pronounced than the reduction in average velocity.

Effects on velocity and duration have to be interpreted by considering the known relationships of these variables with saccadic amplitude (Bahill et al., 1975; Westheimer, 1954), given that lorazepam caused reduced saccadic amplitudes in our data. Therefore, we calculated the ratios of both peak and average velocity as well as duration over saccade amplitude (Sweeney et al., 1997). For the amplitude-corrected measure of peak velocity (log transformed due to positive skew), there was a main effect of Drug ($F[2,64]=7.46$, $p=0.001$, $\eta_p^2=0.19$), confirming above finding. However, there was

no main effect of Drug on amplitude-corrected average velocity ($F[2,64]=0.93$, $p=0.40$, $\eta_p^2=0.03$). For amplitude-corrected duration, a main effect of Drug emerged ($F[2,64]=18.36$, $p<0.001$, $\eta_p^2=0.37$), suggesting that lorazepam increased saccade duration when correcting for amplitude.

Simple contrasts to follow up main effects of Drug revealed that all pairwise differences between placebo, 1mg and 2mg lorazepam were significant (all $p<0.05$), with the exceptions of the contrast placebo vs. 1mg for latency ($p=0.50$), skewness ($p=0.29$), latency ICV ($p=0.08$), duration ICV ($p=0.09$), curvature ICV ($p=0.30$) and the contrast 1mg vs. 2mg for amplitude-corrected peak velocity ($p=0.34$), Q ($p=0.40$) and latency ICV ($p=0.19$).

Study Aim 4.

Before considering the role of Sex in the effects of Drug (Study Aim 4), main effects of Sex were investigated. These revealed that males had greater spatial error, higher skewness and greater ICV of gain than females. For explanatory purposes, higher skewness in males indicates that the onset of peak velocity in the saccade occurred later than in females.

Drug by Sex interactions (Study Aim 4) were observed for spatial error and ICV of gain, indicating stronger negative responses to lorazepam in females than males on both variables (Figure 1). The comparison of 2mg vs. placebo was significant in both males and females for both variables ($p<0.003$), but the comparison of 2mg vs. 1mg was significant only in females for both variables ($p<0.001$) but not in males for either variable ($p>0.12$). The effect of 1mg vs. placebo was significant in females for both variables ($p\leq 0.005$) but not in males for either variable ($p>0.05$). Males had higher spatial error and ICV of gain than females only on placebo (both $p\leq 0.001$), but not on lorazepam (all $p>0.007$, not surviving Bonferroni corrected alpha level of $p=0.0056$).

Study Aim 5.

Study Aim 5 concerns interactions of Drug with the task factors Direction and Distance.

Drug by Direction interactions were observed for average velocity, skewness and Q. For amplitude-corrected average velocity, the interaction became non-significant ($p=0.09$). For amplitude-corrected duration, an interaction arose ($F[2,64]=3.20$, $p=0.047$, $\eta_p^2=0.09$).

For average velocity, the interaction indicated stronger reductions with lorazepam for saccades to the right (all $p<0.002$) than the left (all $p>0.01$; not significant at Bonferroni corrected alpha level of 0.0056). Effects of Direction were significant for placebo ($p<0.001$), but not lorazepam conditions ($p>0.02$).

For skewness, the interaction indicated stronger increases with lorazepam for saccades to the left ($p<0.001$ for 2mg vs. placebo; other $p>0.007$, n.s. at Bonferroni corrected alpha level of $p=0.0056$) than to the right (all $p>0.22$). There were no significant effects of Direction at each level of Drug (all $p>0.01$, n.s.).

For Q, the interaction suggested stronger reductions with lorazepam for saccades to the left ($p<0.001$ for 1mg vs. placebo and for 2mg vs. placebo; other $p=0.19$) than to the right (all $p>0.13$). There was a significant effect of Direction only for 2mg ($p=0.003$; other $p>0.01$, n.s. at Bonferroni corrected alpha level of $p=0.0056$).

For amplitude-corrected duration, the interaction indicated stronger increases with lorazepam for saccades to the right (all $p<0.002$) than the left (1mg vs. placebo: $p=0.60$; 1mg vs. 2mg: $p=0.002$; 2mg vs. placebo: $p=0.004$). Effects of Direction were significant for placebo ($p<0.001$), but not lorazepam conditions ($p>0.03$).

Drug by Distance interactions were observed for gain, peak velocity and Q. Drug by Distance interactions similarly were found for amplitude-corrected average velocity ($F[2,64]=4.38$, $p=0.02$, $\eta_p^2=0.12$) and amplitude-corrected duration ($F[2,64]=3.35$, $p=0.04$, $\eta_p^2=0.10$).

For gain, the interaction indicated stronger reductions with lorazepam for near (all $p<0.004$) than far stimuli, and only the comparison of 2mg vs. placebo reached Bonferroni corrected significance

($p < 0.001$; all other $p > 0.009$ and n.s. at corrected alpha level $p = 0.0056$). Effects of Distance were observed for placebo ($p < 0.001$) and 1mg ($p = 0.004$), but not 2mg ($p = 0.86$).

For peak velocity, the interaction similarly indicated that reductions due to lorazepam were more pronounced for near than far stimuli, with all pairwise comparisons significant for near stimuli (all $p \leq 0.001$), whereas for far stimuli the comparison of 1mg vs. 2mg was not significant ($p = 0.11$; all other $p < 0.001$). Effects of Distance were significant for all Drug conditions (all $p < 0.001$) (Figure 2).

For Q, the interaction suggested a stronger reduction with lorazepam for near than far stimuli. Pairwise comparisons were significant for near stimuli at 2mg vs. placebo ($p = 0.001$) and 1mg vs. placebo (but not surviving Bonferroni corrected alpha level of $p = 0.0056$; $p = 0.02$) but not 1mg vs. 2mg ($p = 0.07$). For far stimuli only the comparison of 2mg vs. placebo was significant ($p = 0.001$; other $p > 0.05$). Effects of Distance were observed for placebo and 1mg (both $p < 0.001$), but not 2mg ($p = 0.01$; not surviving Bonferroni corrected alpha level of $p = 0.0056$).

For amplitude-corrected average velocity, the interaction indicated that reductions due to lorazepam occurred for near (1mg vs. placebo, $p = 0.04$, not surviving Bonferroni corrected alpha level of $p = 0.0056$) but not far stimuli (all $p > 0.58$). Effects of Distance were significant for all Drug conditions (all $p < 0.001$).

For amplitude-corrected duration, effects of Drug were observed at both near and far stimuli (all $p < 0.001$) with the exception of 1mg vs. placebo (both $p > 0.04$, not surviving Bonferroni corrected alpha level of $p = 0.0056$). Effects of Distance were significant for all Drug conditions (all $p < 0.001$).

Finally, there were a number of main effects and interactions involving Direction, Distance and Sex, but not Drug.

Main effects of Direction indicated that saccades to stimuli in the right hemifield had lower spatial error, higher average and peak velocity (also amplitude-corrected), shorter duration (also amplitude-corrected), and higher Q than saccades to stimuli in the left hemifield.

Main effects of Distance indicated that saccades to near stimuli had higher gain, lower average and peak velocity (also amplitude-corrected), shorter duration (also amplitude-corrected), shorter latency, higher skewness, higher Q, higher curvature and higher ICVs of gain, spatial error and peak velocity than saccades to far stimuli.

A Direction by Distance interaction for skewness indicated that greater skewness for saccades to the left than to the right was observed for far ($p=0.002$) but not near ($p=0.75$) stimuli. Effects of Distance were observed for saccades both to the right and to the left (both $p\leq 0.001$).

Direction by Sex interactions were observed for peak velocity, skewness and curvature. For amplitude-corrected peak velocity, however, the interaction was non-significant ($p=0.26$).

For peak velocity, the interaction indicated higher peak velocity for right than left saccades for males ($p<0.001$) but not females ($p=0.10$). Sex differences were not significant for either direction (both $p>0.25$).

For skewness, the interaction indicated greater skewness for left than right saccades for males ($p=0.001$) but not females ($p=0.63$). Sex differences were observed for saccades to the left ($p=0.001$) but not to the right ($p=0.08$).

For curvature, there were no significant post-hoc tests (all $p>0.30$).

A Distance by Sex interaction was observed for average velocity ICV, indicating that the effects of Distance was stronger for females ($p=0.02$; but not surviving Bonferroni corrected alpha level of 0.0125) than for males ($p=0.15$). Males had greater ICV than females for far ($p=0.03$; not surviving Bonferroni corrected level of 0.0125) but not for near ($p=0.52$) stimuli.

Correlations of Baseline Trait Variables with Change Scores

Study Aim 6.

There were no significant correlations of age, intelligence and trait anxiety with change scores from placebo for performance under either 1mg or 2mg lorazepam (all $r < 0.49$, all $p > 0.003$, n.s. at Bonferroni corrected alpha level of 0.0003) (see Supplementary Table 1).

Drug Effects on Internal Consistency

Study Aim 7.

Cronbach's alphas were high for most saccade variables (ranging from 0.75 to 0.94), with the exception of somewhat lower alphas for curvature (ranging from 0.59 to 0.73) (Table 5). There were no significant differences between the Drug conditions in internal consistency of any variables (all $p > 0.02$, n.s. at Bonferroni corrected alpha level of 0.0167).

Discussion

The key findings from this study are as follows. First, we confirmed that lorazepam reduces saccadic peak velocity and we demonstrated that this effect is both sensitive to dose and independent of age, sex, intelligence and trait anxiety. The sensitivity of peak velocity was further underscored by the effect of lorazepam on Q, a measure of the ratio between peak and average velocity, showing that the drug effect was more pronounced on peak than average velocity. Second, lorazepam effects on saccades were widespread, with deteriorations observed on most mean and variability measures. Notably, however, the internal reliability of performance (Cronbach's alpha) was not affected. Third, lorazepam effects interacted with sex on consistency measures of spatial accuracy, indicating more pronounced adverse effects in females. Fourth, there was evidence that lorazepam effects depend on task factors. Effects on peak velocity, gain and Q were more pronounced for near than far stimuli. Effects on average velocity were more pronounced for saccades to the right, whereas effects on skewness and Q were stronger for saccades to the left. Fifth, analysis of dose-dependency showed that most variables were sensitive to both 1mg lorazepam compared to placebo and an increase from 1mg to 2mg. Exceptions were latency, skewness, and the variabilities of latency, duration and curvature, which showed deterioration from placebo only with 2mg, suggesting these measures are less suited to detecting low-dose lorazepam effects.

Lorazepam Effects

Using a multi-dose, within-subjects design, we replicated the well-established finding of reduced saccadic peak velocity following benzodiazepine administration (Study Aim 1). Considering the magnitude of the effect observed in this study and the consistency of this finding across numerous studies using various benzodiazepine compounds (De Visser et al., 2003), we argue that this effect is likely to be one of the most consistent findings in experimental psychopharmacology.

The current study advances this literature in a number of ways. First, we confirmed that the effect on peak velocity is independent of sex, age, intelligence and trait anxiety (Study Aims 4 and 6). The reason for investigating these possible predictor variables lies in the known variability in pharmacological response across individuals and the importance of developing individualised treatment strategies, e.g. by taking into account patients' baseline measurements (Owen et al., 2013). We can thus conclude that the effect of lorazepam on saccadic peak velocity is fundamental, i.e. independent of the participant variables studied here, at least within the range of scores observed in this carefully selected, healthy sample.

Second, we extend previous studies by demonstrating that lorazepam effects on saccades are pronounced, affecting almost all measured aspects of mean and variability of performance (Study Aims 2 and 3). Most previous studies have focussed on peak velocity, and no previous study has investigated a spectrum of variables as comprehensive as that reported here. Therefore, and because our study included multiple doses and a larger sample than most other studies in the field (De Visser et al., 2003), our findings provide an important archive of lorazepam effects across saccadic performance measures. To summarise, lorazepam led to increased latency, reduced spatial accuracy, reduced average velocity, reduced peak/average velocity ratio (Q), increased skewness, increased curvature, and increased intra-individual variabilities of all measures except spatial error. Most variables showed evidence of dose-dependency, except mean latency, mean skewness, latency variability, duration variability and curvature variability for the comparison of placebo vs. 1mg, as well as Q, amplitude-corrected peak velocity and latency variability for the comparison of 1mg vs. 2mg.

Taken together, and comparing these data to the often much more subtle and specific effects of other substances on oculomotor measures (Ettinger and Kumari, 2003; Reilly et al., 2008), the picture that emerges is that benzodiazepines cause a fundamental, nonspecific destabilisation of the neural system controlling saccadic eye movements. The macroscopic neural mechanisms underlying this

effect remain unknown, necessitating functional neuroimaging studies (Minzenberg, 2012; Nathan et al., 2014). The distribution of GABA_A receptors in brain and the observed pattern of lorazepam effects suggest that various structures in the neural network underlying saccades are affected, from cortical eye fields to brainstem.

Specifically, peak velocity is related to activity of burst neurons in the pontine reticular formation (Fuchs et al., 1985), suggesting that the robust reduction of peak velocity in this and other studies is a result of GABAergic effects on brainstem neurons. Saccadic latency, on the other hand, is a composite measure that reflects perceptual processes, attention, target selection, decision making and programming premotor commands and is subject to both top-down and bottom-up influences (Carpenter, 2004; Hutton, 2008). Benzodiazepine effects on saccadic latency have been observed previously (Chen et al., 2014, 2015; de Haas et al., 2009; de Haas et al., 2007, 2008; Green et al., 2000; Masson et al., 2000; Tedeschi et al., 1983). The increase in latency could reflect a delay in the programming of the saccadic command (Masson et al., 2000) and may stem from GABAergic effects in frontal or parietal eye fields (Roy-Byrne et al., 1993; Sommer and Tehovnik, 1997). Reduced spatial accuracy following benzodiazepines has also been observed previously (Chen et al., 2014, 2015; de Haas et al., 2007, 2008, 2009; King et al., 1995; Masson et al., 2000), and might reflect lorazepam's action in frontal eye fields or cerebellum (Glue, 1991; Robinson & Fuchs, 2001; Sommer & Tehovnik, 1997). Effects on curvature may arise in the brainstem (Leigh and Zee, 2015).

Some lorazepam effects interacted with the saccade task factors direction (right/left stimuli) and distance (near/far stimulus positions) (Study Aim 5). Specifically, effects on average velocity were more pronounced for saccades to the right, whereas effects on skewness and Q were stronger for saccades to the left. Effects on gain, peak velocity and Q were more pronounced for near than far stimuli. An important implication of these findings for future drug screening studies using saccadic biomarkers is to include multiple stimulus positions, in order to be able to detect adverse drug effects with maximal sensitivity, especially for comparisons between different drug doses.

Finally, an interesting observation of this study was that the internal reliability (Cronbach's alpha) of performance was not significantly altered by lorazepam (Study Aim 7). This finding suggests that despite the observed increases in intra-individual variability of some measures, performance remained consistent across individuals. An important corollary of this finding is that lorazepam does

not reduce the internal reliability with which saccadic performance is measured, even at a dose of 2mg.

Sex-Dependent Effects of Lorazepam

In addition to these primary effects of lorazepam, there was evidence of sex-dependent effects (Study Aim 4) on two saccadic measures, viz. the intra-individual variability of spatial error and amplitude gain. These findings indicated that adverse effects of lorazepam on these variables were stronger in females than in males. The spatial accuracy of saccades reflects basic sensorimotor transformation processes that rely on cerebellar integrity (Ettinger et al., 2002, 2005; Robinson and Fuchs, 2001).

The finding of sex-dependent lorazepam effects on spatial accuracy may be explained via the drug's action in the cerebellum and sex differences in mediating these effects. Support for this hypothesis comes from a positron emission tomography (PET) study demonstrating sex differences in glucose metabolism in brain following administration of lorazepam (Wang et al., 1998). In that study, bodyweight-adjusted, intravenous administration of lorazepam (30µg/kg) led to similar reductions in overall brain metabolic activity in both females and males. However, a sex effect was observed in cerebellum, where lorazepam-induced reductions tended to be more pronounced in females (-5.9 ±6%) than in males (-1.1 ±6.6%) (Wang et al., 1998). Whilst Wang et al. (1998) did not observe sex-dependent lorazepam effects on motor or cognitive tasks, we agree with their conclusion that “more specific cerebellar tests may have been able to disclose differences between the genders in sensitivity to lorazepam's motor effects” (p. 43) given that we succeeded in showing such effects on saccadic spatial accuracy in our study. It should be noted that men also have larger cerebellar volume than females, even when adjusted for whole-brain volume (Giedd et al., 2012), suggesting they may need a higher dosage to achieve the same occupancy. Interestingly, male>female differences in volume are particularly pronounced in motor-related cerebellar areas such as lobule VIIIIB (Steele and Chakravarty, 2017), an area whose volume we have previously found to be related to saccadic spatial accuracy in healthy humans (Ettinger et al., 2005).

These findings of sex-dependent lorazepam effects suggest that anxiolytic treatment effects may generally differ by sex, an issue that has previously been raised (Bekker and van Mens-Verhulst, 2007; Yonkers et al., 1992). Here, the effects of lorazepam were not observed on a measure of

anxiety, of course, but on an oculomotor measure. Two issues should be raised in this context. First, it is unclear whether sex-dependent drug effects on this measure translate to sex differences in the anxiolytic response in patients with anxiety disorders. Second, it should be noted that males in this study showed worse performance on these measures than females, suggesting that the observed Drug by Sex interaction may reflect a difference in baseline performance, perhaps compatible with sex differences in cerebellar metabolism in the absence of pharmacological challenges (Volkow et al., 1997). Thus, further studies are needed to investigate whether genuine sex differences in drug response are observed, even in the absence of baseline performance differences.

Limitations

The following limitations should be noted. First, we did not measure lorazepam concentrations. These may have been helpful in further characterising pharmacodynamics effects, especially as they may be affected by age or sex. A second limitation is that we did not obtain weight measures of our participants; therefore, it is not possible to relate inter-individual differences in the magnitude of drug effects to body weight.

Conclusions and Implications

To conclude, we confirm that lorazepam dose-dependently reduces saccadic peak velocity. This effect is both robust, not being related to various baseline variables, and sensitive, given that effects on peak velocity were greater than those on average velocity. An important additional conclusion from this study is that lorazepam effects on saccades are pronounced, leading to deteriorations in most measures of saccadic performance investigated here. An implication of this pattern of findings is that studies aiming to detect (adverse) effects of benzodiazepine compounds should include saccadic parameters other than just the peak velocity in order to obtain a full picture of the drug's effects. Additionally, task factors interacted with lorazepam effects, suggesting that the drug exerts negative influences especially at smaller-amplitude saccades. Future studies should thus include multiple target positions in order to optimally probe for benzodiazepine effects. Finally, a noteworthy finding was that effects of lorazepam on measures of spatial consistency were more pronounced for females than males. Whilst this finding of course needs to be replicated, it underscores the importance of including both male and female participants in pharmacological studies.

References

- Abel MH and Brown LK (1998) Validity of the 16PF reasoning scale. *Psychological Reports*, SAGE PublicationsSage CA: Los Angeles, CA 83(3): 904–906.
- Atack JR (2008) GABAA receptor subtype-selective efficacy: TPA023, an $\alpha 2/\alpha 3$ selective non-sedating anxiolytic and $\alpha 5$ 1A, an $\alpha 5$ selective cognition enhancer. *CNS Neuroscience and Therapeutics* 14(1): 25–35.
- Bahill AT, Clark MR and Stark L (1975) The main sequence, a tool for studying human eye movements. *Mathematical Biosciences* 24(3–4): 191–204.
- Ball DM, Glue P, Wilson S, et al. (1991) Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. *Psychopharmacology* 105(3): 361–7.
- Bekker MHJ and van Mens-Verhulst J (2007) Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. *Gender Medicine* 4 Suppl B: S178-93.
- Brooks CE and Clayton JA (2017) Sex/gender influences on the nervous system: Basic steps toward clinical progress. *Journal of Neuroscience Research* 95(1–2): 14–16.
- Carpenter RHS (2004) *Contrast, Probability, and Saccadic Latency: Evidence for Independence of Detection and Decision*. *Current Biology*.
- Cattell R., Eber HW and Tatsuoka MM (1970) *Handbook for the 16 Personality Factor Questionnaire*. Champaign, IL: Institute for Personality and Ability Testing.
- Chen X, De Haas S, De Kam M, et al. (2012) An overview of the CNS-pharmacodynamic profiles of nonselective and selective GABA agonists. *Advances in Pharmacological Sciences*.
- Chen X, Jacobs G, de Kam M, et al. (2014) The central nervous system effects of the partial GABA- $\text{A}\alpha 2,3$ -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. *British Journal of Clinical Pharmacology* 78(6): 1298–314.
- Chen X, Jacobs G, de Kam ML, et al. (2015) AZD6280, a novel partial gamma-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers. *Journal of Clinical Psychopharmacology* 35(1): 22–33.
- Coghill DR, Seth S, Pedroso S, et al. (2014) Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. *Biological Psychiatry* 76(8): 603–15.

- Collewijn H, Erkelens CJ and Steinman RM (1988) Binocular co-ordination of human horizontal saccadic eye movements. *The Journal of Physiology*, Wiley-Blackwell 404: 157–82.
- de Haas S, Franson K, Schmitt J, et al. (2009) The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers. *Journal of Psychopharmacology* 23(6): 625–632.
- de Haas SL, de Visser SJ, van der Post JP, et al. (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. *Journal of Psychopharmacology (Oxford, England)* 21(4): 374–83.
- de Haas SL, de Visser SJ, van der Post JP, et al. (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. *Journal of Psychopharmacology (Oxford, England)* 22(1): 24–32.
- De Visser SJ, Van Der Post JP, De Waal PP, et al. (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. *British Journal of Clinical Pharmacology* 55(1): 39–50.
- Diedenhofen B and Musch J (2016) cocron : A Web Interface and R Package for the Statistical Comparison of Cronbach's Alpha Coefficients. *International Journal of Internet Science* 11(1): 51–60.
- Ettinger U and Kumari V (2003) Pharmacological Studies of Smooth Pursuit and Antisaccade Eye Movements in Schizophrenia: Current Status and Directions for Future Research. *Current Neuropharmacology*, Bentham Science Publishers Ltd. 1(4): 285–300.
- Ettinger U, Kumari V, Chitnis XA, et al. (2002) Relationship between brain structure and saccadic eye movements in healthy humans. *Neuroscience Letters* 328(3): 225–228.
- Ettinger U, Antonova E, Crawford TJ, et al. (2005) Structural neural correlates of prosaccade and antisaccade eye movements in healthy humans. *NeuroImage* 24(2): 487–494.
- Fuchs AF, Kaneko CRS, Scudder CA, et al. (1985) Brainstem Control of Saccadic Eye Movements. *Annual Review of Neuroscience* 8(1): 307–337.
- Giedd JN, Raznahan A, Mills KL, et al. (2012) Review: magnetic resonance imaging of male/female differences in human adolescent brain anatomy. *Biology of Sex Differences* 3(1): 19.
- Glue P (1991) Merck, Sharp & Dohme Prize for Young Psychopharmacologists: The pharmacology of saccadic eye movements. *Journal of Psychopharmacology*, Sage PublicationsSage CA: Thousand Oaks, CA 5(4): 377–387.

- Green JF, King DJ and Trimble KM (2000) Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. *Journal of Psychopharmacology (Oxford, England)* 14(1): 30–6.
- Harron DW, Hasson B, Regan M, et al. (1995) Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. *Journal of Cardiovascular Pharmacology* 26 Suppl 2: S48-54.
- Holmqvist K, Nyström M, Andersson R, et al. (2011) *Eye Tracking*. Oxford: Oxford University Press.
- Hutton SB (2008) Cognitive control of saccadic eye movements. *Brain and Cognition*, Elsevier Inc. 68(3): 327–340.
- Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. (2011) The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. *Epidemiologia e psichiatria sociale* 18(1): 23–33.
- King DJ, Best P, Lynch G, et al. (1995) The effects of remoxipride and chlorpromazine on eye movements and psychomotor performance in healthy volunteers. *Journal of Psychopharmacology (Oxford, England)* 9(2): 143–9.
- Kuntsi J and Klein C (2012) Intraindividual Variability in ADHD and Its Implications for Research of Causal Links. *Current Topics in Behavioral Neurosciences*, pp. 67–91.
- Kyriakopoulos AA, Greenblatt DJ and Shader RI (1978) Clinical pharmacokinetics of lorazepam: a review. *The Journal of clinical psychiatry* 39(10 Pt 2): 16–23.
- Leigh RJ and Zee DS (2015) *The Neurology of Eye Movements*. Oxford University Press.
- Masson GS, Mestre DR, Martineau F, et al. (2000) Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: Attentional and motor factors. *Behavioural Brain Research* 108(2): 169–180.
- Minzenberg MJ (2012) Pharmacological MRI approaches to understanding mechanisms of drug action. *Current Topics in Behavioral Neurosciences* 11: 365–88.
- Nathan PJ, Phan KL, Harmer CJ, et al. (2014) Increasing pharmacological knowledge about human neurological and psychiatric disorders through functional neuroimaging and its application in drug discovery. *Current Opinion in Pharmacology* 14: 54–61.
- Owen DR, Rupprecht R and Nutt DJ (2013) Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? *Journal of Psychopharmacology* 27(2): 119–122.


- Perkins Adam M., Leonard AM, Weaver K, et al. (2013) A dose of ruthlessness: interpersonal moral judgment is hardened by the anti-anxiety drug lorazepam. *Journal of Experimental Psychology. General* 142(3): 612–20.
- Perkins A M, Ettinger U, Weaver K, et al. (2013) Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type. *Translational Psychiatry* 3(4): e246.
- Port NL and Wurtz RH (2003) Sequential activity of simultaneously recorded neurons in the superior colliculus during curved saccades. *Journal of neurophysiology* 90(3): 1887–903.
- Reilly JL, Lencer R, Bishop JR, et al. (2008) Pharmacological treatment effects on eye movement control. *Brain and Cognition*, Elsevier Inc. 68(3): 415–435.
- Robinson FR and Fuchs AF (2001) The role of the cerebellum in voluntary eye movements. *Annual Review of Neuroscience* 24(1): 981–1004.
- Roy-Byrne PP, Cowley DS, Radant A, et al. (1993) Benzodiazepine pharmacodynamics: utility of eye movement measures. *Psychopharmacology* 110(1–2): 85–91.
- Sheliga BM, Riggio L and Rizzolatti G (1994) Orienting of attention and eye movements. *Experimental Brain Research* 98(3): 507–522.
- Smit AC and Van Gisbergen JAM (1990) An analysis of curvature in fast and slow human saccades. *Experimental Brain Research*, Springer-Verlag 81(2): 335–345.
- Sommer MA and Tehovnik EJ (1997) Reversible inactivation of macaque frontal eye field. *Experimental Brain Research*, Springer-Verlag 116(2): 229–249.
- Spielberger CD, Gorsuch RL, Lushene PR, et al. (1983) *Manual for the State-Trait Anxiety Inventory (Form Y)*. Palo Alto, CA: Consulting Psychologists.
- Steele CJ and Chakravarty MM (2017) Gray-matter structural variability in the human cerebellum: Lobule-specific differences across sex and hemisphere. *NeuroImage*.
- Sweeney JA, Bauer KS, Keshavan MS, et al. (1997) Adverse effects of risperidone on eye movement activity: A comparison of risperidone and haloperidol in antipsychotic-naïve schizophrenic patients. *Neuropsychopharmacology* 16(3): 217–228.
- Tannenbaum C, Schwarz JM, Clayton JA, et al. (2016) Evaluating sex as a biological variable in preclinical research: the devil in the details. *Biology of Sex Differences* 7(1): 13.
- Tedeschi G, Smith AT, Dhillon S, et al. (1983) Rate of entrance of benzodiazepines into the brain

- determined by eye movement recording. *British journal of Clinical Pharmacology* 15(1): 103–7.
- Tolin DF and Foa EB (2006) Sex differences in trauma and posttraumatic stress disorder: A quantitative review of 25 years of research. *Psychological Bulletin*, American Psychological Association 132(6): 959–992.
- Uusi-Oukari M and Korpi ER (2010) Regulation of GABAA Receptor Subunit Expression by Pharmacological Agents. *Pharmacological Reviews* 62(1).
- Volkow ND, Wang GJ, Fowler JS, et al. (1997) Gender differences in cerebellar metabolism: Test-retest reproducibility. *American Journal of Psychiatry*, American Psychiatric Publishing 154(1): 119–121.
- Wang GJ, Volkow ND, Fowler JS, et al. (1998) Evaluation of gender difference in regional brain metabolic responses to lorazepam. *Psychiatry Research* 82(1): 37–46.
- Westheimer G (1954) Mechanism of saccadic eye movements. *Archives of Ophthalmology*, American Medical Association 52(5): 710–724.
- Yarbus AL (1967) *Eye Movements and Vision*. Boston, MA: Springer US.
- Yonkers KA, Kando JC, Cole JO, et al. (1992) Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. *American Journal of Psychiatry* 149(5): 587–595.

Acknowledgements


The study was supported by a Medical Research Council (MRC) grant to AMP, VK and SCRW. AMP and SCRW are currently funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience, King's College London. Disclaimer: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. We are grateful to Kristin Weaver, Ania Leonard and Anne Schmechtig for assistance in data collection and to Rachel Ashwick, Pamela Küpper and Erik Lang for assistance in preparing the manuscript. We thank all volunteers for their participation.

Figure 1: Effects of Lorazepam on Spatial Accuracy Measures in Males and Females



Legend: The diagram shows the effects of lorazepam, sex (male, female) and their interaction on (A) variability of amplitude gain and (B) mean spatial error. Data are means, error bars reflect ± 1 standard error. For illustration purposes, untransformed data are shown but statistical analyses were performed on transformed data (see main text). ICV: intra-individual coefficient of variation. N=18 males, N=16 females. # indicates statistical significance following Bonferroni correction and n.s. indicates not significant (see main text for details).

Figure 2: Effects of Lorazepam on Peak Velocity as a Function of Stimulus Position



Legend: The diagram shows the effects of lorazepam and stimulus position (near (7.25°), far (14.5°)) as well as their interaction on saccadic peak velocity (in degrees per second). Data are means, error bars reflect ± 1 standard error. N=34. # indicates statistical significance following Bonferroni correction and n.s. indicates not significant (see main text for details).

Table 1: Sample Characteristics

	Sample Characteristics*
N male/female	18/16
Age (years)	25.06 (4.09)
16PF Reasoning Scale Score	9.47 (1.71)
STAI Trait Anxiety Score	35.21 (9.01)

Legend: *Data are given in mean (SD) unless otherwise stated. The 16PF Reasoning Scale was used as a measure of intelligence (Cattell et al., 1970). The STAI was used to measure trait anxiety (Spielberger et al., 1983). N=34.

Table 2: Descriptive Statistics of Prosaccade Variables – Males

	Placebo				Lorazepam 1mg				Lorazepam 2mg			
	Right, Far (14.5°)	Right, Near (7.25°)	Left, Near (- 7.25°)	Left, Far (-14.5°)	Right, Far (14.5°)	Right, Near (7.25°)	Left, Near (- 7.25°)	Left, Far (-14.5°)	Right, Far (14.5°)	Right, Near (7.25°)	Left, Near (- 7.25°)	Left, Far (-14.5°)
Latency (M)	176.85 (24.56)	155.69 (21.79)	156.88 (22.29)	180.45 (39.87)	175.44 (21.63)	157.58 (19.72)	158.84 (21.52)	173.91 (25.95)	188.00 (20.36)	164.30 (18.79)	160.88 (25.62)	189.28 (28.50)
Amplitude Gain (M)	0.91 (0.05)	0.96 (0.10)	0.92 (0.07)	0.86 (0.06)	0.88 (0.08)	0.92 (0.12)	0.88 (0.10)	0.85 (0.12)	0.85 (0.11)	0.86 (0.12)	0.85 (0.10)	0.81 (0.10)
Spatial Error (M)	0.10 (0.04)	0.11 (0.05)	0.11 (0.05)	0.14 (0.05)	0.13 (0.07)	0.14 (0.08)	0.15 (0.08)	0.17 (0.10)	0.16 (0.10)	0.18 (0.11)	0.18 (0.09)	0.19 (0.10)
Peak Velocity (M)	413.42 (68.96)	322.45 (63.29)	286.84 (42.97)	370.99 (53.91)	383.29 (68.32)	301.68 (53.45)	269.43 (39.54)	342.25 (44.46)	374.95 (71.75)	277.40 (52.62)	252.18 (47.36)	326.61 (50.01)
Average Velocity (M)	219.51 (20.81)	157.87 (20.49)	147.61 (15.98)	203.92 (19.73)	209.07 (27.23)	154.17 (21.61)	146.31 (19.23)	204.17 (27.75)	201.61 (24.58)	141.87 (21.38)	138.83 (20.67)	194.40 (27.66)
Duration (M)	60.95 (4.83)	44.53 (5.17)	45.79 (3.90)	62.03 (3.87)	61.31 (4.89)	43.24 (4.21)	43.87 (3.86)	61.06 (6.13)	61.97 (5.41)	44.38 (6.05)	46.18 (7.16)	62.51 (6.29)
Curvature (M)	0.02 (0.01)	0.03 (0.02)	0.02 (0.02)	0.01 (0.01)	0.02 (0.01)	0.03 (0.02)	0.02 (0.01)	0.02 (0.01)	0.02 (0.01)	0.03 (0.02)	0.02 (0.02)	0.02 (0.01)
Skewness	0.35 (0.06)	0.39 (0.05)	0.39 (0.06)	0.37 (0.07)	0.35 (0.06)	0.39 (0.05)	0.39 (0.06)	0.38 (0.06)	0.35 (0.06)	0.40 (0.05)	0.41 (0.07)	0.41 (0.05)
Q	1.89 (0.31)	2.07 (0.49)	1.96 (0.37)	1.82 (0.22)	1.84 (0.27)	1.97 (0.33)	1.86 (0.30)	1.68 (0.18)	1.86 (0.26)	1.97 (0.32)	1.82 (0.25)	1.68 (0.14)
Latency (ICV)	0.16 (0.07)	0.15 (0.06)	0.15 (0.05)	0.21 (0.14)	0.17 (0.06)	0.18 (0.08)	0.21 (0.10)	0.18 (0.06)	0.21 (0.12)	0.19 (0.12)	0.19 (0.10)	0.25 (0.18)
Amplitude Gain (ICV)	0.09 (0.06)	0.13 (0.08)	0.13 (0.08)	0.14 (0.10)	0.14 (0.09)	0.17 (0.11)	0.17 (0.11)	0.15 (0.11)	0.18 (0.12)	0.21 (0.13)	0.20 (0.12)	0.17 (0.12)

Spatial Error (ICV)	0.80 (0.35)	0.85 (0.23)	0.87 (0.26)	0.78 (0.43)	0.83 (0.30)	0.84 (0.22)	0.85 (0.29)	0.70 (0.31)	0.81 (0.22)	0.85 (0.26)	0.79 (0.18)	0.67 (0.31)
Peak Velocity (ICV)	0.11 (0.08)	0.14 (0.11)	0.15 (0.10)	0.16 (0.11)	0.17 (0.12)	0.18 (0.11)	0.19 (0.09)	0.19 (0.11)	0.23 (0.12)	0.25 (0.15)	0.22 (0.12)	0.25 (0.13)
Average Velocity (ICV)	0.12 (0.06)	0.13 (0.05)	0.13 (0.06)	0.16 (0.09)	0.15 (0.07)	0.16 (0.07)	0.14 (0.06)	0.17 (0.10)	0.21 (0.09)	0.20 (0.08)	0.21 (0.11)	0.21 (0.11)
Duration (ICV)	0.11 (0.07)	0.12 (0.06)	0.12 (0.04)	0.16 (0.11)	0.12 (0.06)	0.13 (0.06)	0.13 (0.07)	0.16 (0.09)	0.18 (0.08)	0.17 (0.09)	0.20 (0.19)	0.18 (0.10)
Curvature (ICV)	1.00 (0.61)	0.83 (0.45)	1.21 (0.80)	1.04 (0.54)	1.08 (0.59)	0.90 (0.46)	0.97 (0.36)	1.06 (0.46)	1.19 (0.56)	1.12 (0.57)	1.21 (0.53)	1.25 (0.62)

Legend: Numbers reflect means (standard deviations); M: mean; ICV: intra-individual coefficient of variation. N=18.

Table 3: Descriptive Statistics of Prosaccade Variables – Females

	Placebo				Lorazepam 1mg				Lorazepam 2mg			
	Right, Far (14.5°)	Right, Near (7.25°)	Left, Near (- 7.25°)	Left, Far (-14.5°)	Right, Far (14.5°)	Right, Near (7.25°)	Left, Near (- 7.25°)	Left, Far (-14.5°)	Right, Far (14.5°)	Right, Near (7.25°)	Left, Near (- 7.25°)	Left, Far (-14.5°)
Latency (M)	178.63 (19.08)	160.76 (14.66)	161.42 (20.44)	179.32 (23.36)	183.53 (15.91)	166.16 (19.97)	165.01 (19.60)	185.14 (27.19)	202.23 (28.43)	181.19 (24.46)	180.14 (28.79)	196.27 (28.77)
Amplitude Gain (M)	0.94 (0.04)	0.98 (0.06)	0.95 (0.07)	0.93 (0.05)	0.92 (0.05)	0.92 (0.05)	0.93 (0.07)	0.90 (0.06)	0.86 (0.08)	0.84 (0.14)	0.86 (0.14)	0.87 (0.12)
Spatial Error (M)	0.07 (0.03)	0.07 (0.03)	0.08 (0.04)	0.08 (0.04)	0.09 (0.05)	0.10 (0.05)	0.10 (0.04)	0.11 (0.05)	0.14 (0.07)	0.19 (0.12)	0.19 (0.09)	0.17 (0.09)
Peak Velocity (M)	403.22 (48.70)	316.30 (33.78)	298.97 (35.45)	393.65 (42.63)	380.34 (57.78)	294.12 (54.21)	285.61 (46.60)	364.02 (61.85)	372.02 (88.78)	262.47 (54.92)	254.32 (59.78)	352.38 (69.25)
Average Velocity (M)	220.67 (17.26)	157.55 (16.55)	145.60 (16.36)	208.67 (22.75)	209.19 (19.81)	145.32 (12.11)	146.18 (10.88)	202.32 (20.23)	196.15 (22.13)	137.62 (15.44)	136.41 (16.85)	195.67 (26.04)
Duration (M)	62.81 (5.45)	45.98 (4.22)	48.16 (5.01)	66.10 (7.45)	64.78 (5.32)	46.73 (3.89)	46.71 (2.95)	66.19 (6.57)	64.79 (4.79)	44.02 (6.55)	46.01 (5.46)	65.84 (6.93)
Curvature (M)	0.01 (0.01)	0.02 (0.01)	0.02 (0.01)	0.02 (0.02)	0.01 (0.01)	0.02 (0.01)	0.02 (0.01)	0.02 (0.01)	0.02 (0.01)	0.02 (0.01)	0.02 (0.01)	0.02 (0.01)
Skewness	0.32 (0.05)	0.36 (0.04)	0.34 (0.04)	0.31 (0.06)	0.31 (0.04)	0.37 (0.04)	0.36 (0.03)	0.32 (0.05)	0.32 (0.05)	0.38 (0.05)	0.38 (0.06)	0.34 (0.06)
Q	1.83 (0.20)	2.03 (0.30)	2.07 (0.28)	1.90 (0.20)	1.82 (0.23)	2.03 (0.35)	1.95 (0.28)	1.80 (0.22)	1.89 (0.40)	1.90 (0.27)	1.85 (0.28)	1.79 (0.20)
Latency (ICV)	0.17 (0.06)	0.15 (0.07)	0.17 (0.07)	0.17 (0.08)	0.15 (0.05)	0.18 (0.07)	0.19 (0.06)	0.19 (0.08)	0.18 (0.07)	0.20 (0.08)	0.21 (0.14)	0.23 (0.16)
Amplitude Gain (ICV)	0.06 (0.06)	0.07 (0.02)	0.08 (0.04)	0.06 (0.03)	0.08 (0.06)	0.12 (0.06)	0.11 (0.04)	0.08 (0.04)	0.11 (0.05)	0.21 (0.15)	0.21 (0.11)	0.16 (0.11)

Spatial Error (ICV)	0.71 (0.45)	0.72 (0.16)	0.69 (0.22)	0.62 (0.23)	0.71 (0.28)	0.85 (0.21)	0.90 (0.36)	0.65 (0.21)	0.72 (0.37)	0.81 (0.27)	0.85 (0.32)	0.76 (0.33)
Peak Velocity (ICV)	0.10 (0.05)	0.09 (0.04)	0.11 (0.05)	0.10 (0.06)	0.15 (0.08)	0.16 (0.08)	0.13 (0.06)	0.14 (0.09)	0.26 (0.34)	0.23 (0.12)	0.22 (0.09)	0.21 (0.09)
Average Velocity (ICV)	0.11 (0.05)	0.10 (0.04)	0.13 (0.05)	0.10 (0.05)	0.13 (0.07)	0.16 (0.06)	0.14 (0.05)	0.12 (0.05)	0.14 (0.06)	0.18 (0.09)	0.19 (0.05)	0.19 (0.09)
Duration (ICV)	0.13 (0.08)	0.10 (0.04)	0.12 (0.06)	0.10 (0.07)	0.12 (0.06)	0.14 (0.07)	0.13 (0.05)	0.13 (0.06)	0.12 (0.05)	0.20 (0.11)	0.17 (0.07)	0.19 (0.14)
Curvature (ICV)	1.08 (0.36)	1.03 (0.55)	1.01 (0.50)	0.92 (0.44)	1.40 (0.53)	0.96 (0.40)	0.99 (0.38)	1.00 (0.52)	1.02 (0.49)	1.06 (0.28)	1.16 (0.56)	1.15 (0.41)

Legend: Numbers reflect means (standard deviations); M: mean; ICV: intra-individual coefficient of variation. N=16.

Table 4: ANOVA Results

	Drug	Direction	Distance	Sex	Drug x Direction	Drug x Distance	Drug x Sex	Direction x Distance	Direction x Sex	Distance x Sex	Drug x Direction x Distance	Drug x Direction x Sex	Drug x Distance x Sex	Direction x Distance x Sex	Drug x Direction x Distance x Sex
Latency (M)	F[2,64]=14.52, p<.001, $\eta_p^2=0.31$	F[1,32]=0.01, p=0.95, $\eta_p^2<0.005$	F[1,32]=15.45, p<.001, $\eta_p^2=0.78$	F[1,32]=2.49, p=0.12, $\eta_p^2=0.07$	F[1.56,49.95]=0.61, p=0.61, $\eta_p^2=0.02$	F[2,64]=1.34, p=0.27, $\eta_p^2=0.04$	F[2,64]=2.18, p=0.12, $\eta_p^2=0.06$	F[1,32]=0.01, p=0.92, $\eta_p^2<0.005$	F[1,32]=0.03, p=0.86, $\eta_p^2<0.005$	F[1,32]=0.75, p=39, $\eta_p^2=0.02$	F[2,64]=0.03, p=0.97, $\eta_p^2<0.005$	F[2,64]=0.09, p.92, $\eta_p^2<0.005$	F[2,64]=1.50, p.23, $\eta_p^2=0.05$	F[1,32]=0.09, p=0.77, $\eta_p^2<0.005$	F[2,64]=0.85, p=0.43, $\eta_p^2=0.03$
Amplitude Gain (M)	F[2,64]=15.59, p<.001, $\eta_p^2=0.33$	F[1,32]=2.53, p=0.12, $\eta_p^2=0.07$	F[1,32]=9.41, p=0.004, $\eta_p^2=0.23$	F[1,32]=2.28, p=0.14, $\eta_p^2=0.07$	F[1.48,47.39]=2.17, p=0.14, $\eta_p^2=0.06$	F[1.64,52.48]=6.97, p=0.004, $\eta_p^2=0.18$	F[2,64]=0.37, p=0.69, $\eta_p^2=0.01$	F[1,32]=0.72, p=0.40, $\eta_p^2=0.02$	F[1,32]=2.10, p=0.16, $\eta_p^2=0.62$	F[1,32]=4.05, p=0.05, $\eta_p^2=0.11$	F[2,64]=1.11, p=0.34, $\eta_p^2=0.03$	F[2,64]=0.31, p=0.74, $\eta_p^2=0.01$	F[2,64]=0.24, p=0.79, $\eta_p^2=0.01$	F[1,32]=0.20, p=0.66, $\eta_p^2=0.01$	F[2,64]=1.50, p=0.23, $\eta_p^2=0.05$
Spatial Error (M)	F[2,64]=32.90, p<.001, $\eta_p^2=0.51$	F[1,32]=6.44, p=0.02, $\eta_p^2=0.17$	F[1,32]=0.84, p=0.37, $\eta_p^2=0.03$	F[1,32]=5.97, p=0.02, $\eta_p^2=0.16$	F[2,64]=0.64, p=0.53, $\eta_p^2=0.02$	F[2,64]=1.86, p=0.16, $\eta_p^2=0.06$	F[2,64]=4.31, p=0.02, $\eta_p^2=0.12$	F[1,32]=2.31, p=0.13, $\eta_p^2=0.07$	F[1,32]=0.16, p=0.70, $\eta_p^2=0.01$	F[1,32]=1.13, p=0.30, $\eta_p^2=0.03$	F[2,64]=0.24, p=0.79, $\eta_p^2=0.01$	F[2,64]=0.02, p=0.98, $\eta_p^2<0.005$	F[2,64]=0.41, p=0.67, $\eta_p^2=0.01$	F[1,32]=0.87, p=0.36, $\eta_p^2=0.03$	F[2,64]=1.17, p=0.32, $\eta_p^2=0.04$
Peak Velocity (M)	F[2,64]=21.13, p<.001, $\eta_p^2=0.40$	F[1,32]=21.04, p<.001, $\eta_p^2=0.40$	F[1,32]=733.49, p<.001, $\eta_p^2=0.96$	F[1,32]=0.10, p=0.76, $\eta_p^2<0.005$	F[1.34,42.83]=0.03, p=0.93, $\eta_p^2<0.005$	F[1.52,48.52]=3.25, p=0.06, $\eta_p^2=0.09$	F[2,64]=0.06, p=0.94, $\eta_p^2<0.005$	F[1,32]=2.78, p=0.11, $\eta_p^2=0.08$	F[1,32]=4.80, p=0.04, $\eta_p^2=0.13$	F[1,32]=1.80, p=0.19, $\eta_p^2=0.05$	F[1.37,43.79]=1.13, p=0.31, $\eta_p^2=0.03$	F[2,64]=0.02, p=0.99, $\eta_p^2<0.005$	F[2,64]=0.88, p=0.42, $\eta_p^2=0.03$	F[1,32]=81, p=0.37, $\eta_p^2=0.26$	F[2,64]=0.18, p=0.83, $\eta_p^2=0.01$
Average Velocity (M)	F[2,64]=14.88, p<.001, $\eta_p^2=0.32$	F[1,32]=11.61, p=0.002, $\eta_p^2=0.27$	F[1,32]=1852.56, p<.001, $\eta_p^2=0.98$	F[1,32]=08, p=0.78, $\eta_p^2<0.005$	F[1.68,53.60]=7.68, p=0.002, $\eta_p^2=0.19$	F[2,64]=0.82, p=0.45, $\eta_p^2=0.03$	F[2,64]=0.29, p=0.75, $\eta_p^2=0.01$	F[1,32]=0.66, p=0.42, $\eta_p^2=0.02$	F[1,32]=0.53, p=0.47, $\eta_p^2=0.02$	F[1,32]=1.18, p=0.29, $\eta_p^2=0.04$	F[2,64]=0.03, p=0.98, $\eta_p^2<0.005$	F[2,64]=0.22, p=0.80, $\eta_p^2=0.01$	F[2,64]=0.19, p=0.83, $\eta_p^2=0.01$	F[1,32]<0.005, p=0.98, $\eta_p^2<0.005$	F[2,64]=2.19, p=0.12, $\eta_p^2=0.06$
Duration (M)	F[2,64]=0.15, p=0.87, $\eta_p^2=0.01$	F[1,32]=5.53, p=0.26, $\eta_p^2=0.15$	F[1,32]=1059.58, p<.001, $\eta_p^2=0.97$	F[1,32]=3.97, p=0.06, $\eta_p^2=0.11$	F[2,64]=1.77, p=0.18, $\eta_p^2=0.05$	F[1.64,52.41]=2.34, p=0.11, $\eta_p^2=0.07$	F[2,64]=1.97, p=0.15, $\eta_p^2=0.06$	F[1,32]=0.02, p=0.88, $\eta_p^2<0.005$	F[1,32]=0.58, p=0.45, $\eta_p^2=0.02$	F[1,32]=2.80, p=0.10, $\eta_p^2=0.08$	F[2,64]=0.76, p=0.47, $\eta_p^2=0.02$	F[2,64]=0.34, p=0.71, $\eta_p^2=0.01$	F[2,64]=1.16, p=0.32, $\eta_p^2=0.04$	F[1,32]=0.68, p=0.42, $\eta_p^2=0.02$	F[2,64]=0.26, p=0.77, $\eta_p^2=0.01$
Curvature (M)	F[1.67,53.36]=0.20, p=0.78, $\eta_p^2=0.01$	F[1,32]=0.58, p=0.45, $\eta_p^2=0.02$	F[1,32]=28.56, p<.001, $\eta_p^2=0.47$	F[1,32]=1.11, p=0.30, $\eta_p^2=0.03$	F[2,64]=0.34, p=0.71, $\eta_p^2=0.01$	F[2,64]=0.10, p=0.91, $\eta_p^2<0.005$	F[2,64]=2.67, p=0.08, $\eta_p^2=0.08$	F[1,32]=3.45, p=0.07, $\eta_p^2=0.10$	F[1,32]=5.06, p=0.03, $\eta_p^2=0.14$	F[1,32]<0.005, p=0.96, $\eta_p^2<0.005$	F[2,64]=0.321, p=0.73, $\eta_p^2=0.01$	F[2,64]=0.28, p=0.75, $\eta_p^2=0.01$	F[2,64]=1.28, p=0.29, $\eta_p^2=0.04$	F[1,32]=1.81, p=0.19, $\eta_p^2=0.05$	F[2,64]=0.07, p=0.93, $\eta_p^2<0.005$
Skewness	F[2,64]=6.85, p=0.002, $\eta_p^2=0.18$	F[1,32]=4.05, p=0.05, $\eta_p^2=0.11$	F[1,32]=67.60, p<.001, $\eta_p^2=0.68$	F[1,32]=8.43, p=0.01, $\eta_p^2=0.21$	F[2,64]=3.45, p=0.04, $\eta_p^2=0.10$	F[2,64]=0.06, p=0.94, $\eta_p^2=0.01$	F[2,64]=0.01, p=0.99, $\eta_p^2=0.01$	F[1,32]=11.93, p=0.002, $\eta_p^2=0.27$	F[1,32]=7.88, p=0.01, $\eta_p^2=0.20$	F[1,32]=3.32, p=0.08, $\eta_p^2=0.09$	F[2,64]=2.13, p=0.13, $\eta_p^2=0.06$	F[2,64]=0.32, p=0.73, $\eta_p^2=0.01$	F[2,64]=0.66, p=0.52, $\eta_p^2=0.02$	F[1,32]=1.10, p=0.03, $\eta_p^2=0.03$	F[2,64]=0.26, p=0.78, $\eta_p^2=0.01$

						$\eta^2 < 0.005$	$\eta^2 < 0.005$								
Q	F[2,64]=7.94, $p < 0.001$, $\eta^2 = 0.20$	F[1,32]=6.31, $p = 0.02$, $\eta^2 = 0.17$	F[1,32]=47.74, $p < 0.001$, $\eta^2 = 0.60$	F[1,32]=0.29, $p = 0.60$, $\eta^2 = 0.01$	F[2,64]=7.05, $p = 0.002$, $\eta^2 = 0.18$	F[1.65,52.91]=4.60, $p = 0.02$, $\eta^2 = 0.13$	F[2,64]=0.37, $p = 0.69$, $\eta^2 = 0.01$	F[1,32]=04, $p = 0.84$, $\eta^2 < 0.005$	F[1,32]=3.48, $p = 0.07$, $\eta^2 = 0.10$	F[1,32]=07, $p = 0.79$, $\eta^2 < 0.005$	F[2,64]=0.82, $p = 0.44$, $\eta^2 = 0.03$	F[2,64]=0.28, $p = 0.76$, $\eta^2 = 0.01$	F[2,64]=2.55, $p = 0.09$, $\eta^2 = 0.07$	F[1,32]=47, $p = 0.50$, $\eta^2 = 0.02$	F[2,64]=0.48, $p = 0.62$, $\eta^2 = 0.02$
Latency (ICV)	F[2,64]=4.64, $p = 0.01$, $\eta^2 = 0.13$	F[1,32]=2.72, $p = 0.11$, $\eta^2 = 0.08$	F[1,32]=0.85, $p = 0.37$, $\eta^2 = 0.03$	F[1,32]=0.03, $p = 0.86$, $\eta^2 < 0.005$	F[2,64]=0.62, $p = 0.54$, $\eta^2 = 0.02$	F[2,64]=1.76, $p = 0.18$, $\eta^2 = 0.05$	F[2,64]=0.06, $p = 0.94$, $\eta^2 < 0.005$	F[1,32]=1.70, $p = 0.20$, $\eta^2 = 0.05$	F[1,32]=0.05, $p = 0.83$, $\eta^2 < 0.005$	F[1,32]=0.58, $p = 0.45$, $\eta^2 = 0.02$	F[2,64]=0.50, $p = 0.61$, $\eta^2 = 0.02$	F[2,64]=0.03, $p = 0.97$, $\eta^2 < 0.005$	F[2,64]=0.29, $p = 0.75$, $\eta^2 = 0.01$	F[1,32]=0.27, $p = 0.61$, $\eta^2 = 0.01$	F[2,64]=1.64, $p = 0.20$, $\eta^2 = 0.05$
Amplitude Gain (ICV)	F[2,64]=31.93, $p < 0.001$, $\eta^2 = 0.50$	F[1,32]=2.21, $p = 0.15$, $\eta^2 = 0.07$	F[1,32]=30.26, $p < 0.001$, $\eta^2 = 0.49$	F[1,32]=10.72, $p = 0.003$, $\eta^2 = 0.25$	F[2,64]=0.32, $p = 0.73$, $\eta^2 = 0.01$	F[2,64]=0.93, $p = 0.40$, $\eta^2 = 0.03$	F[2,64]=4.25, $p = 0.02$, $\eta^2 = 0.12$	F[1,32]=0.20, $p = 0.66$, $\eta^2 = 0.01$	F[2,64]=0.06, $p = 0.81$, $\eta^2 < 0.005$	F[1,32]=2.80, $p = 0.10$, $\eta^2 = 0.08$	F[2,64]=0.13, $p = 0.88$, $\eta^2 < 0.005$	F[2,64]=1.51, $p = 0.23$, $\eta^2 = 0.05$	F[2,64]=0.23, $p = 0.80$, $\eta^2 = 0.01$	F[1,32] < 0.005, $p = 0.99$, $\eta^2 < 0.005$	F[1,32]=1.31, $p = 0.28$, $\eta^2 = 0.04$
Spatial Error (ICV)	F[2,64]=0.60, $p = 0.55$, $\eta^2 = 0.02$	F[1,32]=1.3, $p = 0.26$, $\eta^2 = 0.04$	F[1,32]=16.53, $p < 0.001$, $\eta^2 = 0.34$	F[1,32]=1.21, $p = 0.28$, $\eta^2 = 0.04$	F[2,64] < 0.005, $p = 0.10$, $\eta^2 < 0.005$	F[2,64]=0.74, $p = 0.48$, $\eta^2 = 0.02$	F[2,64]=2.29, $p = 0.11$, $\eta^2 = 0.07$	F[1,32]=2.36, $p = 0.14$, $\eta^2 = 0.07$	F[1,32]=0.76, $p = 0.39$, $\eta^2 = 0.02$	F[1,32]=0.41, $p = 0.53$, $\eta^2 = 0.01$	F[2,64]=0.21, $p = 0.81$, $\eta^2 = 0.01$	F[2,64]=1.27, $p = 0.29$, $\eta^2 = 0.04$	F[2,64]=58, $p = 0.56$, $\eta^2 = 0.02$	F[1,32]=0.10, $p = 0.75$, $\eta^2 < 0.005$	F[2,64]=0.08, $p = 0.92$, $\eta^2 < 0.005$
Peak Velocity (ICV)	F[2,64]=26.27, $p < 0.001$, $\eta^2 = 0.45$	F[1,32]=0.75, $p = 0.39$, $\eta^2 = 0.02$	F[1,32]=4.30, $p = 0.05$, $\eta^2 = 0.12$	F[1,32]=1.46, $p = 0.24$, $\eta^2 = 0.04$	F[2,64]=2.22, $p = 0.12$, $\eta^2 = 0.07$	F[2,64]=0.15, $p = 0.86$, $\eta^2 = 0.01$	F[2,64]=0.66, $p = 0.52$, $\eta^2 = 0.02$	F[1,32]=0.42, $p = 0.52$, $\eta^2 = 0.01$	F[1,32]=1.51, $p = 0.23$, $\eta^2 = 0.05$	F[1,32]=0.20, $p = 0.66$, $\eta^2 = 0.01$	F[2,64]=0.21, $p = 0.81$, $\eta^2 = 0.01$	F[2,64]=0.94, $p = 0.40$, $\eta^2 = 0.03$	F[2,64]=0.41, $p = 0.67$, $\eta^2 = 0.01$	F[1,32]=2.64, $p = 0.11$, $\eta^2 = 0.08$	F[2,64]=0.21, $p = 0.81$, $\eta^2 = 0.01$
Average Velocity (ICV)	F[2,64]=0.60, $p = 0.55$, $\eta^2 = 0.02$	F[1,32]=1.30, $p = 0.26$, $\eta^2 = 0.04$	F[1,32]=16.53, $p < 0.001$, $\eta^2 = 0.34$	F[1,32]=1.21, $p = 0.28$, $\eta^2 = 0.04$	F[2,64] < 0.005, $p = 0.10$, $\eta^2 < 0.005$	F[2,64]=0.74, $p = 0.48$, $\eta^2 = 0.02$	F[2,64]=2.29, $p = 0.11$, $\eta^2 = 0.07$	F[1,32]=2.36, $p = 0.14$, $\eta^2 = 0.07$	F[1,32]=0.76, $p = 0.39$, $\eta^2 = 0.02$	F[1,32]=0.41, $p = 0.53$, $\eta^2 = 0.01$	F[1,32]=0.21, $p = 0.81$, $\eta^2 = 0.01$	F[2,64]=1.27, $p = 0.29$, $\eta^2 = 0.04$	F[2,64]=0.58, $p = 0.56$, $\eta^2 = 0.02$	F[1,32]=0.10, $p = 0.75$, $\eta^2 < 0.005$	F[1,32]=0.08, $p = 0.92$, $\eta^2 < 0.005$
Duration (ICV)	F[2,64]=12.83, $p < 0.001$, $\eta^2 = 0.29$	F[1,32]=1.68, $p = 0.21$, $\eta^2 = 0.05$	F[1,32]=0.21, $p = 0.65$, $\eta^2 = 0.01$	F[1,32]=0.52, $p = 0.48$, $\eta^2 = 0.02$	F[2,64]=0.09, $p = 0.92$, $\eta^2 < 0.005$	F[2,64]=0.38, $p = 0.69$, $\eta^2 = 0.01$	F[2,64]=0.66, $p = 0.52$, $\eta^2 = 0.02$	F[1,32]=2.06, $p = 0.16$, $\eta^2 = 0.06$	F[1,32]=0.29, $p = 0.59$, $\eta^2 = 0.01$	F[1,32]=1.97, $p = 0.17$, $\eta^2 = 0.06$	F[2,64]=0.96, $p = 0.39$, $\eta^2 = 0.03$	F[2,64]=1.71, $p = 0.19$, $\eta^2 = 0.05$	F[2,64]=0.20, $p = 0.82$, $\eta^2 = 0.01$	F[1,32]=0.30, $p = 0.59$, $\eta^2 = 0.01$	F[2,64]=2.65, $p = 0.08$, $\eta^2 = 0.08$
Curvature (ICV)	F[2,64]=5.44, $p = 0.01$, $\eta^2 = 0.15$	F[1,32]=0.18, $p = 0.68$, $\eta^2 = 0.01$	F[1,32]=2.28, $p = 0.14$, $\eta^2 = 0.07$	F[1,32]=0.12, $p = 0.73$, $\eta^2 < 0.005$	F[1.65,52.88]=0.90, $p = 0.40$, $\eta^2 = 0.03$	F[2,64]=2.05, $p = 0.14$, $\eta^2 = 0.06$	F[2,64]=1.52, $p = 0.23$, $\eta^2 = 0.05$	F[1,32]=3.44, $p = 0.07$, $\eta^2 = 0.10$	F[1,32]=2.34, $p = 0.14$, $\eta^2 = 0.07$	F[1,32]=0.06, $p = 0.81$, $\eta^2 < 0.005$	F[2,64]=2.22, $p = 0.12$, $\eta^2 = 0.07$	F[2,64]=1.65, $p = 0.20$, $\eta^2 = 0.05$	F[2,64]=0.34, $p = 0.71$, $\eta^2 = 0.01$	F[1,32]=0.02, $p = 0.89$, $\eta^2 < 0.005$	F[2,64]=1.17, $p = 0.32$, $\eta^2 = 0.04$

Legend: M: mean; ICV: intra-individual coefficient of variation. N=34.

Table 5: Cronbach's Alpha Results

	Placebo	Lorazepam 1mg	Lorazepam 2mg	Statistical Comparison
Latency	0.83	0.85	0.80	Pla=1mg, p=0.62 Pla=2mg, p=0.75 1mg=2mg, p=0.42
Amplitude Gain	0.81	0.87	0.86	Pla=1mg, p=0.29 Pla=2mg, p=0.46 1mg=2mg, p=0.74
Spatial Error	0.78	0.84	0.81	Pla=1mg, p=0.36 Pla=2mg, p=0.70 1mg=2mg, p=0.60
Peak Velocity	0.94	0.93	0.91	Pla=1mg, p=0.60 Pla=2mg, p=0.26 1mg=2mg, p=0.55
Average Velocity	0.89	0.90	0.87	Pla=1mg, p=0.98 Pla=2mg, p=0.51 1mg=2mg, p=0.49
Duration	0.82	0.83	0.81	Pla=1mg, p=0.86 Pla=2mg, p=0.82 1mg=2mg, p=0.69
Curvature	0.73	0.60	0.59	Pla=1mg, p=0.26 Pla=2mg, p=0.23 1mg=2mg, p=0.95
Skewness	0.88	0.82	0.75	Pla=1mg, p=0.27 Pla=2mg, p=0.04 1mg=2mg, p=0.32
Q	0.94	0.93	0.87	Pla=1mg, p=0.60 Pla=2mg, p=0.03 1mg=2mg, p=0.09

Legend: No comparison reached significance at Bonferroni corrected level of $p=0.0167$. Pla=placebo. N=34.